Synthesis and Structure-Activity Relationships of Long-acting β2 Adrenergic Receptor Agonists Incorporating Metabolic Inactivation: An Antedrug Approach

被引:79
作者
Procopiou, Panayiotis A. [1 ]
Barrett, Victoria J. [2 ]
Bevan, Nicola J. [2 ]
Biggadike, Keith [1 ]
Box, Philip C. [1 ]
Butchers, Peter R. [2 ]
Coe, Diane M. [1 ]
Conroy, Richard [1 ]
Emmons, Amanda [2 ]
Ford, Alison J. [2 ]
Holmes, Duncan S. [1 ]
Horsley, Helen [1 ]
Kerr, Fern [1 ]
Li-Kwai-Cheung, Anne-Marie [1 ]
Looker, Brian E. [1 ]
Mann, Inderjit S. [5 ]
McLay, Iain M. [3 ]
Morrison, Valerie S. [2 ]
Mutch, Peter J. [4 ]
Smith, Claire E. [4 ]
Tomlin, Paula [1 ]
机构
[1] GlaxoSmithKline Med Res Ctr, Dept Med Chem, Stevenage SG1 2NY, Herts, England
[2] GlaxoSmithKline Med Res Ctr, Dept Resp Biol, Stevenage SG1 2NY, Herts, England
[3] GlaxoSmithKline Med Res Ctr, Dept Computat Struct Chem, Stevenage SG1 2NY, Herts, England
[4] GlaxoSmithKline Med Res Ctr, Dept Drug Metab & Pharmacokinet, Resp CEDD, Stevenage SG1 2NY, Herts, England
[5] GlaxoSmithKline, Synth Chem, Old Powder Mills, Tonbridge TN11 9AN, Kent, England
关键词
BETA(2)-ADRENOCEPTOR AGONISTS; INHALED CORTICOSTEROIDS; CRYSTAL-STRUCTURE; DISCOVERY; SALMETEROL; DURATION; ASTHMA;
D O I
10.1021/jm100326d
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of saligenin beta(2) adrenoceptor agonist antedrugs having high clearance were prepared by reacting a protected saligenin oxazolidinone with protected hydroxyethoxyalkoxyalkyl bromides, followed by removal of the hydroxy-protecting group, alkylation, and final deprotection. The compounds were screened for beta(2), beta(1), and beta(3) agonist activity in CHO cells. The onset and duration of action in vitro of selected compounds were assessed on isolated superfused guinea pig trachea. Compound 13f had high potency, selectivity, fast onset, and long duration of action in vitro and was found to have long duration in vivo, low oral bioavailability in the rat, and to be rapidly metabolized. Crystalline salts of 13f (vilanterol) were identified that had suitable properties for inhaled administration. A proposed binding mode for 13f to the beta(2)-receptor is presented.
引用
收藏
页码:4522 / 4530
页数:9
相关论文
共 35 条
[1]   Novel glucocorticoid antedrugs possessing a 21-(γ-lactone) ring [J].
Angell, RM ;
Biggadike, K ;
Farrell, RM ;
Flack, SS ;
Hancock, AP ;
Irving, WR ;
Lynn, SM ;
Procopiou, PA .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 2002, (06) :831-839
[2]   Immunology of asthma and chronic obstructive pulmonary disease [J].
Barnes, Peter J. .
NATURE REVIEWS IMMUNOLOGY, 2008, 8 (03) :183-192
[3]   Efficacy of inhaled corticosteroids in asthma [J].
Barnes, PJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 102 (04) :531-538
[4]   In vitro and in vivo pharmacological characterization of 5-[(R)2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a novel inhaled β2 adrenoceptor agonist with a 24-h duration of action [J].
Battram, C ;
Charlton, SJ ;
Cuenoud, B ;
Dowling, MR ;
Fairhurst, RA ;
Farr, D ;
Fozard, JR ;
Leighton-Davies, JR ;
Lewis, CA ;
McEvoy, L ;
Turner, RJ ;
Trifilieff, A .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 317 (02) :762-770
[5]   The contribution of the swallowed fraction of an inhaled dose of salmeterol to it systemic effects [J].
Bennett, JA ;
Harrison, TW ;
Tattersfield, AE .
EUROPEAN RESPIRATORY JOURNAL, 1999, 13 (02) :445-448
[6]   Novel glucocorticoid antedrugs possessing a C16,17-fused γ-lactone ring [J].
Biggadike, K ;
Lynn, SM ;
Procopiou, PA ;
Shaw, RE ;
Williamson, C .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 1, 2000, (05) :813-818
[7]   Selective plasma hydrolysis of glucocorticoid γ-lactones and cyclic carbonates by the enzyme paraoxonase:: An ideal plasma inactivation mechanism [J].
Biggadike, K ;
Angell, RM ;
Burgess, CM ;
Farrell, RM ;
Hancock, AP ;
Harker, AJ ;
Irving, WR ;
Ioannou, C ;
Procopiou, PA ;
Shaw, RE ;
Solanke, YE ;
Singh, OMP ;
Snowden, MA ;
Stubbs, RJ ;
Walton, S ;
Weston, HE .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (01) :19-21
[8]  
BIGGADIKE K, 1999, Patent No. 9901467
[9]   Drug targeting via retrometabolic approaches [J].
Bodor, N ;
Buchwald, P .
PHARMACOLOGY & THERAPEUTICS, 1997, 76 (1-3) :1-27
[10]   Effects of inhaled corticosteroids on the consequences of asthma [J].
Boushey, HA .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 102 (04) :S5-S16